Cyclic intravenous pamidronate for an infant with osteogenesis imperfecta type II.
Kyoko FukahoriJun NireiKaoru YamawakiKeisuke NagasakiPublished in: BMJ case reports (2023)
A woman in her 30s underwent a 17-week ultrasound which revealed short bowed long bones. Fetal CT at 28 weeks' gestation showed decreased ossification of the skull, a small bell-shaped thorax, hypoplastic vertebrae, and shortening and bowing of the long bones, leading to the diagnosis of osteogenesis imperfecta (OI) type II. The newborn was delivered via caesarean delivery, and tracheal intubation was performed due to the respiratory distress. A heterozygous variant in COL1A1 (c.1679G>T, p. Gly358Val) was ascertained, confirming the diagnosis of OI type II.Cyclic intravenous pamidronate was started at 41 days old with dose modification and was successfully administered every month. Currently, the infant is 8 months old without any new bone fracture. He was extubated successfully at 7 months of age and is now stable using high flow nasal cannula. The efficacy, safety, and optimal dose and timing of cyclic pamidronate for OI type II remain undefined. We report our experience of successful cyclic intravenous pamidronate treatment for an infant with OI type II.
Keyphrases
- high dose
- magnetic resonance imaging
- computed tomography
- bone regeneration
- cardiac arrest
- gestational age
- preterm infants
- bone mineral density
- early onset
- case report
- randomized controlled trial
- extracorporeal membrane oxygenation
- respiratory failure
- postmenopausal women
- positive airway pressure
- positron emission tomography
- contrast enhanced
- study protocol
- single cell
- intensive care unit
- respiratory tract
- magnetic resonance
- smoking cessation
- ultrasound guided
- mechanical ventilation